z-logo
open-access-imgOpen Access
In Vitro Chemotherapeutic Combinations Against Isoniazid-Resistant Mycobacterium tuberculosis and Mycobacterium fortuitum
Author(s) -
Elliot Goldstein,
M. Carroll Eagle,
Mary Lou Lacasse
Publication year - 1971
Publication title -
applied microbiology
Language(s) - English
Resource type - Journals
ISSN - 0003-6919
DOI - 10.1128/am.22.3.329-333.1971
Subject(s) - isoniazid , ethionamide , antimycobacterial , mycobacterium fortuitum , cycloserine , mycobacterium tuberculosis , ethambutol , kanamycin , tuberculosis , microbiology and biotechnology , capreomycin , antibiotics , medicine , pharmacology , mycobacterium , biology , pathology
It is an acceptable medical practice to use second-line antimycobacterial drugs in combination with isoniazid in treatment of isoniazid-resistant tuberculosis. Recent investigations have demonstrated the importance of determining chemotherapeutic interaction in instances of multiple antibiotic use. We studied the inhibitory effect of combinations of isoniazid with ethambutol, rifampin, ethionamide, cycloserine, viomycin, and kanamycin against three isoniazid-resistant strains ofMycobacterium tuberculosis and three strains ofM. fortuitum. The isobologram technique with drug concentrations of 0.4 to 100 μg/ml was used. With the exception of single instances in which kanamycin plus isoniazid (M. tuberculosis strain 9999) and ethionamide plus isoniazid (M. fortuitum strain 2080) seemed to have a synergistic effect, neither synergy nor antagonism was noted for any of the combinations. These studies show that the combined use of isoniazid and a second line antimycobacterial agent results in vitro in indifferent inhibitory activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom